Back to Search
Start Over
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
- Source :
- Neuro-Oncology Advances; Jan-Dec2024, Vol. 6 Issue 1, p1-12, 12p
- Publication Year :
- 2024
Details
- Language :
- English
- Volume :
- 6
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Neuro-Oncology Advances
- Publication Type :
- Academic Journal
- Accession number :
- 182368842
- Full Text :
- https://doi.org/10.1093/noajnl/vdae068